The regulatory clearances that have been conducted in both the U.S. and China, demonstrating the momentum behind SNUG01's global development. Through strategic collaborations and scientific rigor, ...

a gene therapy it's developing as a treatment for amyotrophic lateral sclerosis (ALS). The Beijing-based biotech plans to launch a Phase I/IIa trial in the US and China to evaluate the safety and ...

In that moment, things clicked. A year ago, my father died after an absolutely brutal battle with amyotrophic lateral ...

By decoding neural signals linked to a person’s inner monologue, researchers enabled communication for individuals with ...

In a recent study, scientists successfully decoded not only the words people tried to say but the words they merely imagined saying.

A new discovery about mutations in a gene that causes ALS may allow researchers to design targeted therapies, a study found.

The Company plans to hold an end-of-Phase 2 Type B meeting with the FDA in the third quarter of 2025. This meeting will review results from the Phase 2 VISIONARY-MS trial and discuss the planned Phase ...

When approached for a quote about Jeffrey D Rothstein, Professor of Neurology and Neuroscience and Director of the Brain Science Institute at Johns Hopkins School of Medicine (Baltimore MD, USA), his ...

Sharon Stone emotionally detailed her years-long friendship with Eric Dane, including how she supported him in landing his ...

Stone will be joining Dane — whom she has been friends with "for a long time" — on the long-awaited third season of the HBO ...

Answer ALS, in collaboration with ALS Therapy Development Institute (ALS TDI) and Augie's Quest, today announced plans to ...

Long-term exposure to sulfur dioxide, an air pollutant generated by the burning of fossil fuels, increases the risk of ALS, a ...